Biologicals did not
become a panacea for treatment of Big Pharma's R&D crisis. It is
obvious that when this fact will be clear for the majority investors
the biotech bubble will burst. Can it happen already 2013? Well,
probably... To postpone this inevitable development of the situation
there is a tendency to improve the image of the biotech like as in
case of this
article.
Bank
on 2013 being a year when real innovators in life sciences with bold
ideas look like smart businesspeople, too.
Don't
let the spate of recent venture rounds in the lead-up to Christmas
fool you. The biotech industry has a money problem, and it's not
going to disappear in 2013.
In
an innovative industry like biotech, the absence of venture backing
is a big deal. And without a new crop of drug developers to take the
place of the companies that are being bought out or fail, there will
be fewer deals to do in the future. And that means fewer promising
drugs for Big Pharma to take up the pipeline.
Like
every other industry, biotech is cyclical. But lean times get
tiresome. They also threaten to do some lasting damage to the complex
ecosystem that supports a diverse group of players.
The message? Biotech
bubble needs some more money, otherwise... Are you prepared for this
”otherwise”?
No comments:
Post a Comment